tirzepatide alzheimer clinical trial Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss

23.54

★★★★☆4.8 (126)

Weight Loss: Zepbound More Effective Than Wegovy, Clinical Trial Shows

22.44

★★★★★4.9 (98)

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial - Merola

27.85

★★★★★5.0 (157)

Could a diabetes drug be the key to stopping Alzheimer's?

28.12

★★★★★4.7 (84)

Semaglutide vs. Tirzepatide for Obesity

21.30

★★★★★4.9 (203)

Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study

29.63

★★★★★5.0 (176)

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 trial

26.94

★★★★★4.8 (132)